Viral Hepatitis

You have full text access to this OnlineOpen article

Effect of hepatitis C virus and its treatment on survival†‡

  1. Adeel A. Butt1,2,3,§,*,
  2. Xiaoqiang Wang2,
  3. Charity G. Moore1

Article first published online: 9 JUL 2009

DOI: 10.1002/hep.23000

Issue

Hepatology

Hepatology

Volume 50, Issue 2, pages 387–392, August 2009

Additional Information

How to Cite

Butt, A. A., Wang, X. and Moore, C. G. (2009), Effect of hepatitis C virus and its treatment on survival. Hepatology, 50: 387–392. doi: 10.1002/hep.23000

Author Information

  1. 1

    University of Pittsburgh School of Medicine, Pittsburgh, PA

  2. 2

    Veterans Administration (VA) Pittsburgh Healthcare System, Pittsburgh, PA

  3. 3

    Center for Health Equity Research and Promotion, Pittsburgh, PA

  1. §

    fax: 412-648-6399.

*3601 Fifth Avenue, Suite 3A, Pittsburgh, PA 15213

  1. †

    The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.

  2. ‡

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 29 JUL 2009
  2. Article first published online: 9 JUL 2009
  3. Manuscript Accepted: 24 MAR 2009
  4. Manuscript Received: 21 NOV 2008

Funded by

  • National Institutes of Health/National Institute on Drug Abuse. Grant Number: DA016175-01A1
  • VA Pittsburgh Healthcare System
  • VA Information Resource center
  • National Patient Care Database
  • Decisions Support System database
  • Pharmacy Benefits Management database

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (339K)

References

  • 1
    Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther 2005; 3: 241–249.
  • 2
    El Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. HEPATOLOGY 2002; 36(5 Suppl 1 ): S74–S83.
    Direct Link:
  • 3
    El Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127(5 Suppl 1 ): S27–S34.
  • 4
    Bonino F. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998 May 23; 351: 1535–1539.
  • 5
    Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357: 196–197.
  • 6
    Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001; 15: 689–698.
    Direct Link:
  • 7
    Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167: 743–750.
  • 8
    Neal KR, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56: 1098–1104.
  • 9
    Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, et al. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 105–111.
  • 10
    Harris HE, Ramsay ME, Andrews N, Eldridge KP. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002; 324: 450–453.
  • 11
    Backus LI, Phillips BR, Boothroyd DB, Mole LA, Burgess J, Rigsby MO, et al. Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 39: 613–619.
  • 12
    Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. HEPATOLOGY 2005; 41: 779–789.
    Direct Link:
  • 13
    Batty DS Jr, Swanson SJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001; 1: 179–184.
    Direct Link:
  • 14
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889–896.
  • 15
    Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1669–1674.
  • 16
    Butt AA, Skanderson M, McGinnis KA, Ahuja TS, Bryce C, Barnato AE, et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat 2007; 14: 688–696.
  • 17
    Campos NG, Salomon JA, Servoss JC, Nunes DP, Samet JH, Freedberg KA, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007; 120: 272–279.
  • 18
    Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
  • 19
    Zeuzem S, Feinman SV, Rasenack J, Heathcote J, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–1672.
  • 20
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
  • 21
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.
  • 22
    Butt AA, Justice AC, Skanderson M, Rigsby M, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385–389.
  • 23
    Butt AA, Khan UA, McGinnis KA, Skanderson M, Kwoh CK. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 2007; 14: 890–896.
  • 24
    Butt AA, Justice AC, Skanderson M, Good CB, Kwoh CK. Rates and predictors of HCV treatment in HCV-HIV coinfected persons. Aliment Pharmacol Ther 2006; 24: 585–591.
    Direct Link:
  • 25
    An Introduction to Survival Analysis Using Stata. 2nd ed. College Station, TX: Stata Press; 2008.
  • 26
    Butt AA, Khan UA, Skanderson M. Comorbidities and their impact on mortality in HCV and HCV-HIV co-infected persons on dialysis. J Clin Gastroenterol 2008; 42: 1054–1059.
  • 27
    Cawthorne CH, Rudat KR, Burton MS, Brown KE, Luxon BA, Janney CG, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002; 97: 149–155.
    Direct Link:
  • 28
    Nguyen HA, Miller AI, Dieperink E, Willenbring ML, Tetrick LL, Durfee JM, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002; 97: 1813–1820.
    Direct Link:
  • 29
    Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol 2000; 95: 740–747.
    Direct Link:
View Full Article (HTML) Get PDF (339K)